A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran

Forootan H¹ ; Sharifi A¹ ; Mirmomen SH¹ ; Daryani N¹ ; Ghofrani H¹ ; Farahvash M¹ ; Nasiri M¹ ; Talebi M² ; Ghavidel A³ ; Vosoghinia H⁴ ; Mansourghanaei F⁵ ; Zahedi M⁶ ; Mirmomen H⁷ ; Azmi M⁷ Show All Authors

Forootan H¹
Sharifi A¹
Mirmomen SH¹
Daryani N¹
Ghofrani H¹
Farahvash M¹
Nasiri M¹
Talebi M²
Ghavidel A³
Vosoghinia H⁴
Mansourghanaei F⁵
Zahedi M⁶
Mirmomen H⁷
Azmi M⁷
Amirian M⁸
Gharb S⁹

Source: Medical Journal of the Islamic Republic of Iran Published:2005

Abstract

Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first-line treatment of chronic hepatitis C. Methods: A total of 97 treatment-naive patients received Heberon three million units thrice-weekly subcutaneously in combination with ribavirin for 12 months. Serum HCV RNA levels were measured before and during therapy and 6 months after the end of therapy. End-of-treatment and sustained virological responses was defined as an undetectable HCV-RNA level at the end of treatment, and 6 months after treatment was completed (end of follow-up), respectively. Results: In an intent-to-treat analysis, HCV-RNA was undetectable at the end of treatment in 49.5% of patients. At the end of follow-up, sustained virological response was 36.1%. Combination treatment was generally well tolerated. Six patients stopped therapy because of side effects: severe cytopenia (n=4), depression (n=1), and hyperthyroidism (n=1). Common side effects of therapy include: Flu-like syndrome (85.6%), generalized alopecia (41.2%), injection site inflammation (37.1%), mood changes (36%), anorexia (34%) and weight loss (32%). Conclusion: Heberon as an IFN product in combination with ribavirin for treatment of patients with chronic hepatitis C is relatively safe, feasible, and potentially efficacious. It has comparable results in achieving end-of-treatment and sustained virological responses in chronic hepatitis C.

Related Docs

View other Related Docs

1. Efficacy of Triple Therapy With Interferon Alpha-2B, Ribavirin and Amantadine in the Treatment of Naive Patients With Chronic Hepatitis C, Journal of Research in Medical Sciences (2007)

2. Relative Frequency of Early Virologic Response to Treatment With a Combination of Conventional Interferon and Ribavirin in Patients With Chronic Hepatitis C, Journal of Isfahan Medical School (2012)

3. Efficacy of Interferon Alpha-2B With or Without Ribavirin in Thalassemia Major Patients With Chronic Hepatitis C Virus Infection: A Randomized, Double Blind, Controlled, Parallel Group Trial, Journal of Research in Medical Sciences (2010)

Experts (# of related papers)

View all Related Experts

Hamid Kalantari (9)

Mohammad Minakari (5)

Other Related Docs

4. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial, Clinical Infectious Diseases (2020)

5. The Interleukin 28B Gene Polymorphism, Rs8099917, in Patients With Chronic Hepatitis C and Response to the Treatment With Pegylated Interferon and Ribavirin, Journal of Research in Medical Sciences (2019)

6. Interleukin-28B (Rs12979860) Gene Variation and Treatment Outcome After Peginterferon Plus Ribavirin Therapy in Patients With Genotype 1 of Hepatitis C Virus, Journal of Research in Medical Sciences (2014)

7. Statin Efficacy in the Treatment of Hepatitis C Genotype I, Journal of Research in Medical Sciences (2014)

8. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)

9. Correlation Between Vitamin D3 Level and Extrahepatic Manifestation in Chronic Hepatitis Type-C Virus Patients, Journal of Research in Medical Sciences (2018)

10. Hepatic Steatosis in Iranian Patients With Chronic Hepatitis C, Medical Principles and Practice (2008)

11. Anti-Hepatitis E Antibody in Hemodialysis Patients in Isfahan, Iran: Prevalence and Risk Factors, Hepatitis Monthly (2015)

12. The Relationship Between Hcv-Ns5a Gene Mutations and Resistance to Combination Therapy in Patients With Hcv- Genotype 1-B, Reports of Biochemistry and Molecular Biology (2021)

14. Seroprevalence of Hepatitis a in Patients With Chronic Hepatitis C in Isfahan Province, International Journal of Preventive Medicine (2012)

15. Effects of Silybum Marianum on Patients With Chronic Hepatitis C, Journal of Research in Medical Sciences (2011)

16. Erratum: Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase Iii Clinical Trial (Clin Infect Dis (2020) 70:10 (2206-2212) Doi: 10.1093/Cid/Ciz628), Clinical Infectious Diseases (2021)

17. The Estimation of Direct Medical Costs of Treating Patients With Chronic Hepatitis B and C in Iran, International Journal of Preventive Medicine (2012)

18. Identification of Patients With Hepatitis C Virus Infection in Persons With Background of Intravenous Drug Use: The First Community Announcementbased Study From Iran, International Journal of Preventive Medicine (2012)

19. Hepatitis C Virus Genotype Frequency in Isfahan Province of Iran: A Descriptive Cross-Sectional Study, Virology Journal (2010)

20. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran, Hepatitis Monthly (2017)

Style	Citing Format
MLA	Forootan H, et al.. "A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran." Medical Journal of the Islamic Republic of Iran, vol. 19, no. 1, 2005, pp. 7-12.
APA	Forootan H, Sharifi A, Mirmomen SH, Daryani N, Ghofrani H, Farahvash M, Nasiri M, Talebi M, Ghavidel A, Vosoghinia H, Mansourghanaei F, Zahedi M, Mirmomen H, Azmi M, Amirian M, Gharb S (2005). A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran. Medical Journal of the Islamic Republic of Iran, 19(1), 7-12.
Chicago	Forootan H, Sharifi A, Mirmomen SH, Daryani N, Ghofrani H, Farahvash M, Nasiri M, et al.. "A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran." Medical Journal of the Islamic Republic of Iran 19, no. 1 (2005): 7-12.
Harvard	Forootan H et al. (2005) 'A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran', Medical Journal of the Islamic Republic of Iran, 19(1), pp. 7-12.
Vancouver	Forootan H, Sharifi A, Mirmomen SH, Daryani N, Ghofrani H, Farahvash M, et al.. A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran. Medical Journal of the Islamic Republic of Iran. 2005;19(1):7-12.
BibTex	@article{ author = {Forootan H and Sharifi A and Mirmomen SH and Daryani N and Ghofrani H and Farahvash M and Nasiri M and Talebi M and Ghavidel A and Vosoghinia H and Mansourghanaei F and Zahedi M and Mirmomen H and Azmi M and Amirian M and Gharb S}, title = {A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran}, journal = {Medical Journal of the Islamic Republic of Iran}, volume = {19}, number = {1}, pages = {7-12}, year = {2005} }
RIS	TY - JOUR AU - Forootan H AU - Sharifi A AU - Mirmomen SH AU - Daryani N AU - Ghofrani H AU - Farahvash M AU - Nasiri M AU - Talebi M AU - Ghavidel A AU - Vosoghinia H AU - Mansourghanaei F AU - Zahedi M AU - Mirmomen H AU - Azmi M AU - Amirian M AU - Gharb S TI - A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran JO - Medical Journal of the Islamic Republic of Iran VL - 19 IS - 1 SP - 7 EP - 12 PY - 2005 ER -